Alison Moskowitz
lymphoma therapeutics
Alison Moskowitz, MD
New York, NY
United States
Memorial Sloan Kettering Cancer Center
Dr. Alison Moskowitz is an Associate Attending and Clinical Director of the Lymphoma service at Memorial Sloan Kettering Cancer Center. She earned her medical degree at Albert Einstein College of Medicine, completed an internship and residency in internal medicine at Columbia University Medical Center, and completed fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Dr. Moskowitz’s research is dedicated to developing new treatment strategies for T-cell lymphoma and relapsed/refractory Hodgkin lymphoma. The T-cell lymphomas are rare diseases that are typically associated with poor prognosis. She aims to develop new agents for T-cell lymphoma through clinical trials that incorporate strong correlative studies aimed at identifying markers of sensitivity and resistance. These studies will allow us to design personalized treatment approaches, predict optimal combination strategies, and ultimately improve prognosis by rationally designing regimens that target the diverse T-cell lymphoma entities.
Program Name(s)
Career Development Program
Project Title
JAK/STAT inhibition as a therapeutic strategy in T-cell lymphoma
_dam_file_128861.jpg?crop=true&keep=n&w=336&h=336)
Jianhua Yu
myeloma immunotherapy
Jianhua Yu, PhD
Duarte, CA
United States
Beckman Research Institute of the City of Hope
Jianhua Yu, PhD, is a Professor and Founding Director of the Natural Killer (NK) Cell Research Program at City of Hope. Dr. Yu is internationally recognized for his fundamental contributions in understanding NK cell biology. Dr. Yu published pioneer studies on chimeric antigen receptor (CAR) NK cells as early as 2013. Dr. Yu’s team developed a process to engineer NK cells including those possessing a CAR for “off-the-shelf” clinical use. Dr. Yu also makes significant contributions to oncolytic virotherapy and conducts CAR-T cell research. Dr. Yu holds over 20 patents (awarded or pending) on his research that are highly applicable to the clinic, some of which are licensed to pharmaceutical companies. Dr. Yu has over 200 peer-reviewed publications with nearly 14,000 citations to date, notably senior-author ones on original studies in high-impact journals such as Nature Biotechnology, Nature Immunology, Cancer Discovery, Immunity, etc. Dr. Yu was a scholar of LLS and ACS and the recipient of the Jack Latham Innovative Research Award from the National Blood Foundation.
Program Name(s)
Career Development Program
Project Title
Trent Hall
MDS
Trent Hall, PhD
Memphis, TN
United States
St. Jude Children's Research Hospital
Dr. Trent Hall is currently a Postdoctoral Research Associate in the laboratory of Dr. John Crispino at St. Jude Children’s Research Hospital in Memphis, TN. Dr. Hall received his doctorate from the University of Tennessee Health Science Center in 2020 studying hematopoietic stem cell development in Dr. Shannon McKinney-Freeman’s laboratory. Dr. Hall’s current research interests include predisposition to myeloid malignancies and hematopoietic development.
Program Name(s)
Career Development Program
Project Title
Identifying novel regulators of leukemic progression in GATA2-deficiency syndrome
Immunitas Therapeutics
immunotherapy, DLBCL, Hodgkin's
Immunitas Therapeutics
Waltham, MA
United States
TAP Partner
Immunitas is a single cell genomics-based therapeutics company focused on immunology that is advancing multiple programs to the clinic. Immunitas’ programs are derived from their platform, a cross-functional, highly integrated, single cell genomics approach that enables rapid target identification and validation in parallel with antibody discovery and engineering.
Program Name(s)
Therapy Acceleration Program
Project Title
Daniel Thomas
Myelofibrosis
Daniel Thomas, MD PhD
Adelaide,
Australia
The University of Adelaide
Associate Professor Daniel Thomas is a Stanford-trained physician scientist who leads the Myeloid Metabolism Laboratory in the Precision Medicine Theme of the South Australian Health and Medical Research Institute at the University of Adelaide, Australia. As a clinician, Dan is passionate about direct bench to bedside translation and leads several innovative mutation-directed precision medicine clinical trials for blood cancers in Australia. Dan has published more than 48 peer-reviewed papers and he has received 16 prizes for his research including the Albert-Baikie Medal and highly competitive funding (CSL Centenary Fellowship, Snowdome and K99-R00 NCI Pathway to Independence award.
Program Name(s)
Translational Research Program
Project Title
Identification and Molecular Analysis of Pre-Myelofibrotic Stem Cells
Caroline Arber
myeloma CAR-T
Caroline Arber, MD
Lausanne,
Switzerland
Centre Hospitalier Universitaire Vaudois
Caroline Arber obtained her Doctor of Medicine from the University of Basel, Switzerland, and specialized in Internal Medicine and Hematology, with a focus on hematologic malignancies and stem cell transplant. To dive into the T cell engineering field, she moved to the Center for Cell and Gene Therapy, Baylor College of Medicine, USA, where she was a research fellow (2010-2014) and an Assistant Professor (2014-2017). Since 2017 she is an Associate Professor, Research Group leader and Attending Physician at the Lausanne University Hospital, University of Lausanne and Ludwig Institute for Cancer Research Lausanne, Switzerland. She leads a translational research group investigating novel T cell engineering strategies for hematologic malignancies. She also studies the impact of the bone marrow immune microenvironment on outcomes of CAR T cell therapies in myeloma. She has published several last author papers in journals such as Blood, JITC, Cancer Immunology Research, Science Advances.
Program Name(s)
Translational Research Program
Project Title
Designed biosensor to enhance CAR T cell therapy for multiple myeloma
Sergei Doulatov
Leukemias
Sergei Doulatov, PhD
New York, NY
United States
Columbia University Medical Center
Dr. Doulatov is an Associate Professor at the University of Washington. His laboratory investigates how normal hematopoietic stem cells (HSCs) transform into blood cancers. As an undergraduate at UCLA with Dr. Jeff Miller, he discovered a new class of retroelements. As a Ph.D. student with Dr. John Dick at the University of Toronto, he helped establish the “roadmap” of the human HSC and progenitor hierarchy. As a postdoctoral fellow with Dr. George Daley at Harvard, he identified methods to promote HSC development from induced pluripotent stem cells (iPSCs). These advances have enabled the use of iPSCs as a platform for disease modeling and drug screens, leading to the discovery of a drug for inherited anemia. The Doulatov laboratory is using human iPSCs and HSCs to discover how oncogenic mutations cooperate to transform normal stem cells into leukemias. His long-term goal is to develop treatments that target malignant stem cells leading to lasting remissions for patients.
Program Name(s)
Career Development Program
Project Title
Modeling and targeting leukemic transformation of human hematopoietic stem cells
Stefan Tarnawsky, MD, PhD
St. Louis, MO
United States
Washington University in St. Louis
Stefan Tarnawsky, M.D.; Ph.D. is a Hematology/Oncology fellow and junior physician scientist at the Washington University School of Medicine in Saint Louis, MO. His research focus is understanding the origin of myeloid blood cancers. His graduate work at Indiana University with Dr. Merv Yoder and Dr. Rebecca Chan focused on the prenatal origin of childhood blood cancers. This work led to a F30 award from the NHLBI and three first-author research publications, including one in the Journal of Clinical Investigations. Currently, under the mentorship of Dr. Matt Walter, M.D., Stefan studies how splicing factor gene mutations dysregulate blood cell growth. He thereby aims to identify novel therapies for the ~50% of myelodysplastic syndrome patients and ~20% of acute myeloid leukemia patients that have these mutations. His career goal is to continue this research focus as an independent investigator studying and treating blood cancer patients at an academic medical center.
Program Name(s)
Career Development Program
Project Title
Catriona Jamieson
cancer stem cell biology
Catriona Jamieson, MD, PhD
La Jolla, CA
United States
The Regents of the University of California, San Diego
Catriona Jamieson, MD, PhD is a leading physician-scientist in the cancer stem cell biology field. She is a professor of medicine, the Koman Family Presidential Endowed Chair in Cancer Research, deputy director of the Moores Cancer Center and the director of the Sanford Stem Cell Clinical Center at the University of California San Diego (UCSD). Dr. Jamieson is the director of the California Institute for Regenerative Medicine (CIRM) Alpha Stem Cell Clinic at UCSD, which provides infrastructure to accelerate the bench to bedside development and implementation of cancer stem cell targeted and cellular immunotherapy trials for hematologic and other malignancies. Dr. Jamieson’s discoveries and pioneering cancer stem cell research have informed the development of cancer stem cell targeted therapies, including JAK2 and sonic hedgehog inhibitor trials, which resulted in two FDA approvals for myeloproliferative neoplasms (MPNs) and leukemia
Program Name(s)
Discovery
Project Title
Detection and Targeting of Enzymatic Base Editing Deregulation in Leukemia Stem Cells
Lindsey Montefiori
pediatric leukemia
Lindsey Montefiori, PhD
Memphis, TN
United States
St. Jude Children's Research Hospital
I am a postdoctoral researcher in Dr. Charles Mullighan’s laboratory at St. Jude Children’s Research Hospital. My research interests lie in understanding how changes in our DNA disrupt normal blood cell development to cause leukemia. I started my research career as a postbaccalaureate fellow at the NIH where I studied how B cells tightly control DNA damage and repair to generate diverse antibodies. I attended the University of Chicago for my PhD where I used next generation sequencing technology to study how DNA elements called enhancers control the activity of developmentally-regulated genes, which are often mutated in cancer. In my postdoctoral research at St. Jude, I am studying a rare, high-risk form leukemia that has features of both myeloid (e.g. AML) and lymphoid (e.g. ALL) disease. My research uses human blood cells, patient samples, and mouse models to investigate how specific DNA alterations lead to this form of leukemia and identify new tailored therapeutic approaches.
Program Name(s)
Career Development Program
Project Title
Molecular basis and new therapeutic strategies in lineage ambiguous leukemia
.jpg?crop=true&keep=n&w=336&h=336)
Vijay Sankaran, MD, PhD
Boston, MA
United States
Boston Children's Hospital
Vijay G. Sankaran, MD, PhD is the Jan Ellen Paradise, MD Professor of Pediatrics at Harvard Medical School, an Investigator of the Howard Hughes Medical Institute, an Attending Physician in the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and an Associate Member of the Broad Institute. Dr. Sankaran's lab seeks to understand the influence of human genetic variation on blood and immune cell production in health and disease. Their work has resulted in a number of therapies for blood diseases, including work that led to the development of Casgevy for sickle cell disease and beta-thalassemia. Dr. Sankaran has received a number of awards for his work including the 2019 Seldin-Smith Award for Pioneering Research from the American Society of Clinical Investigation, the 2022 E. Mead Johnson Award from the Society for Pediatric Research, and 2024 Trailblazer Prize from the Foundation for the National Institutes of Health.
Program Name(s)
Discovery
Project Title
Patrizia Mondello
IgM MGUS & Waldenstrom Macroglobulinemia
Patrizia Mondello, MD, PhD
Rochester, MN
United States
Mayo Clinic
I am a physician-scientist focusing on the biology and therapeutic targeting of B-cell lymphoma. I trained in Medical Oncology in Italy. Given my interest in the molecular mechanisms underlying cancer development, I enrolled in a PhD program in Cellular Biology and Experimental Medicine at Memorial Sloan Kettering (MSK). I explored the impact of novel therapeutic agents aimed at disrupting well-defined oncogenic signaling pathways. I pursued postdoctoral studies at Weill Cornell. The focus of my postdoctoral research was aberrant epigenetic programming and development of precision therapies in B-cell lymphoma. I then honed my clinical expertise in lymphoma as an advanced fellow at MSK. I further enhanced my research skills in immunotherapy and epigenetic as an advanced fellow at Mayo Clinic. Most recently, I have started my independent research program at Mayo Clinic focusing on epigenetic dysregulations in B cell malignancies and their impact on the tumor microenvironment.
Program Name(s)
Special Grants